International Stem Cell Corporation announced that its wholly owned subsidiary, Lifeline Cell Technology (LCT), has expanded its business and manufacturing capabilities to fulfill current and forecasted demand. In 2017 alone, LCT’s annual revenue growth outperformed 2016 by over 20 percent. And in Q1 2018, LCT experienced more than a 50 percent increase in sales growth from the prior year quarter. During this time, several projects have been completed that greatly improved LCT’s man...